Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Average Price Target of $17.75

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have been given a consensus rating of “Hold” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.75.

Several analysts recently commented on TRDA shares. Roth Capital restated a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. HC Wainwright reiterated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, UBS Group restated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th.

Entrada Therapeutics Price Performance

NASDAQ:TRDA opened at $5.44 on Thursday. The firm has a market cap of $212.98 million, a price-to-earnings ratio of -1.42 and a beta of -0.19. The company has a 50 day moving average price of $5.68 and a 200-day moving average price of $8.48. Entrada Therapeutics has a 1-year low of $4.11 and a 1-year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Thursday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.07. Entrada Therapeutics had a negative net margin of 4,057.98% and a negative return on equity of 64.00%. The firm had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $2.30 million. On average, sell-side analysts anticipate that Entrada Therapeutics will post -4.16 earnings per share for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the transaction, the insider owned 3,913,952 shares in the company, valued at approximately $29,002,384.32. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total value of $199,975.88. Following the transaction, the insider owned 4,332,917 shares in the company, valued at $32,670,194.18. This represents a 0.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 495,947 shares of company stock valued at $3,600,470 in the last ninety days. 9.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its stake in Entrada Therapeutics by 14.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 26,776 shares of the company’s stock valued at $170,000 after acquiring an additional 3,326 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Entrada Therapeutics by 24.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 116,596 shares of the company’s stock worth $740,000 after acquiring an additional 23,058 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Entrada Therapeutics by 118.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 60,704 shares of the company’s stock worth $380,000 after acquiring an additional 32,926 shares during the period. Odyssean LLC acquired a new position in Entrada Therapeutics during the second quarter worth $230,000. Finally, Nantahala Capital Management LLC acquired a new position in Entrada Therapeutics during the second quarter worth $2,212,232. 86.39% of the stock is owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments. Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.